FUNDAMENTALS · Fundamentals · US Healthcare

The Oncology Institute (TOI) Fundamentals 2026 — Revenue Analysis | SniperIQ

The Oncology Institute (TOI) is a US-listed Healthcare company in Medical - Care Facilities with a market capitalization of $531M, trading at $5.31 on the NASDAQ. This SniperIQ fundamentals page covers The Oncology Institute's valuation, profitability (net margin -8.0%), revenue ($503M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap$531M
Net Margin-8.0%
Revenue (FY25)$503M

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is The Oncology Institute's market cap?

The Oncology Institute (TOI) has a market capitalization of approximately $531M, trading at $5.31 on the NASDAQ. Market cap moves with the live share price.

How profitable is The Oncology Institute?

The Oncology Institute runs a net profit margin of -8.0%, a gross margin of 14.8%, and an operating margin of -6.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does The Oncology Institute generate?

The Oncology Institute reported revenue of $503M for fiscal year 2025, with net income of -$61M and earnings per share (EPS) of -0.54. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does The Oncology Institute pay a dividend?

The Oncology Institute does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is The Oncology Institute financially healthy?

The Oncology Institute carries a debt-to-equity ratio of -6.44x and a current ratio of 1.47x, with a market beta of 0.39. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is The Oncology Institute a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For The Oncology Institute (TOI) the key facts are: market cap $531M, revenue $503M, 52-week range 2.32-6.67. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track The Oncology Institute's full fundamentals live

Get The Oncology Institute's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Myriad Genetics (MYGN) fundamentals · Arvinas (ARVN) fundamentals · Mesa Laboratories (MLAB) fundamentals · REGENXBIO (RGNX) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons